{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:12:57Z","timestamp":1771481577229,"version":"3.50.1"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary liver cancer (PLC) is the third leading cause of cancer mortality worldwide. The heterogeneity of PLC and the complex immunosuppressive microenvironment make it difficult for single treatment regimens to meet patient needs. Therefore, it is crucial to find effective combination treatment strategies that enhance immune function in PLC therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically evaluate the effect of compound kushen injection (CKI) on enhancing immune function in PLC patients and its role in treatment efficacy and related adverse reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Relevant Chinese and English electronic databases were searched to include randomized controlled trials (RCTs) assessing the impact of CKI on immune function in PLC patients published before June 2025. The quality of the included studies was assessed using the Cochrane risk of bias assessment tool. Statistical analyses, Sensitivity analysis and publication bias assessment were conducted using Stata 18.0 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 2,359 patients from 25 RCTs were included (1,185 in the experimental group and 1,174 in the control group). Compared to conventional treatment alone, the combination of CKI and conventional treatment significantly enhanced immune function, as evidenced by increased CD3\n                      <jats:sup>+<\/jats:sup>\n                      levels, CD4\n                      <jats:sup>+<\/jats:sup>\n                      levels, CD4\n                      <jats:sup>+<\/jats:sup>\n                      \/CD8\n                      <jats:sup>+<\/jats:sup>\n                      ratio, and natural killer (NK) cell levels, while CD8\n                      <jats:sup>+<\/jats:sup>\n                      levels showed no statistical significance. Additionally, CKI improved the objective response rate (ORR) and disease control rate (DCR), reduced AFP levels, increased KPS scores and the one-year overall survival period, reduced treatment-related adverse reactions, including nausea and vomiting, hepatic dysfunction, myelosuppression, fever, and pain.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Existing evidence suggests that the combined use of CKI and conventional treatment may positively impact immune function, therapeutic effect and treatment-related adverse reactions in patients with PLC. However, the reliability of these conclusions is limited by the absence of disease staging stratification analysis and long-term follow-up data, which are essential for confirming the long-term efficacy and safety of the combined treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251112494<\/jats:ext-link>\n                      , identifier CRD420251112494.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1715798","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:22:59Z","timestamp":1771478579000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of compound kushen injection on immune function in patients with primary liver cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yu","family":"Xiong","sequence":"first","affiliation":[{"name":"Department of Tumor, Chongqing Hospital of the First Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Chongqing, China"]},{"name":"Postdoctoral Research Station, Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutong","family":"Cai","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Chongqing University of Chinese Medicine","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxi","family":"Li","sequence":"additional","affiliation":[{"name":"School of Acupuncture and Tuina, Chongqing University of Chinese Medicine","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Yan","sequence":"additional","affiliation":[{"name":"Postdoctoral Research Station, Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]},{"name":"State Key Laboratory of Traditional Chinese Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiongwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Tumor, Chongqing Hospital of the First Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Tumor, Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3969\/j.issn.1007-8517.2018.20.zgmzmjyyzz201820029","article-title":"Clinical observation on transcatheter arterial chemoembolization combined with compound kushen injection in the treatment of 42 cases of primary liver cancer","volume":"27","author":"Ba","year":"2018","journal-title":"Chin. J. Ethnomed Ethnopharm"},{"key":"B2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/coc.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3969\/j.issn.1002-7386.2011.18.033","article-title":"Clinical analysis of TACE combined with compound Kushen injection in the treatment of primary liver cancer","volume":"33","author":"Cao","year":"2011","journal-title":"Hebei Med. J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12943-024-02101-z","article-title":"Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma","volume":"23","author":"Chan","year":"2024","journal-title":"Mol. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2017.05.001","article-title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study","volume":"81","author":"Chau","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3969\/j.issn.1671-038X.2007.04.010","article-title":"Efficacy observation of compound Kushen injection as adjuvant therapy in double interventional treatment of primary liver cancer","author":"Chen","year":"2007","journal-title":"Chin. J. Integr. Tradit. West Med. Dig."},{"key":"B8","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3969\/j.issn.1000-484X.2019.06.008","article-title":"Oxymatrine enhances the sensitivity of breast cancer MCF-7 cells to the cytotoxicity of NK-92MI cells","volume":"35","author":"Chen","year":"2019","journal-title":"Chin. J. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"Ed000142","DOI":"10.1002\/14651858.Ed000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.20047\/j.issn1673-7210.2020.35.036","article-title":"Analysis of adverse reactions and safe medication of compound Kushen injection based on literature reports","volume":"17","author":"Dian","year":"2020","journal-title":"China Med. Her."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.13192\/j.issn.1000-1719.2016.12.033","article-title":"Clinical study on Compound Kushen injection combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer","volume":"43","author":"Dong","year":"2016","journal-title":"Liaoning J. Tradit. Chin. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","article-title":"Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation","volume":"112","author":"Du","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3321\/j.issn:1001-5302.2006.06.022","article-title":"Clinical study on Yanshu Injection combined with chemotherapy in the treatment of advanced primary liver cancer","volume":"31","author":"Guan","year":"2006","journal-title":"China J. Chin. Mater Med."},{"key":"B14","first-page":"51","article-title":"Effect observation of compound Kushen injection as adjuvant therapy in transcatheter arterial chemoembolization for primary liver cancer","volume":"6","author":"Guo","year":"2015","journal-title":"J. Massage Rehabil. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3969\/j.issn.1005-7072.2012.01.04","article-title":"Efficacy observation of compound Kushen injection combined with interventional chemotherapy in the treatment of primary liver cancer and its influence on immune function","volume":"19","author":"Han","year":"2012","journal-title":"Chin. J. Tradit. Med. Sci. Technol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3969\/j.issn.1005-0264.2020.04.005","article-title":"Preventive effect of compound Kushen injection on postoperative recurrence of primary liver cancer and analysis of survival function","volume":"30","author":"Hao","year":"2020","journal-title":"Chin. J. Integr. Tradit. West Med. Liver Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.3969\/j.issn.1001-1528.2016.08.008","article-title":"Effect of Compound Kushen Injection on immune function of patients with primary liver cancer after hepatectomy","volume":"38","author":"He","year":"2016","journal-title":"Chin. Tradit. Pat. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3969\/j.issn.1001-5930.2019.07.037","article-title":"Effect of Compound Kushen Injection combined with apatinib on clinical efficacy, quality of life and safety in patients with advanced non-small cell lung cancer","volume":"34","author":"Hou","year":"2019","journal-title":"J. Pract. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","article-title":"Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment","volume":"31","author":"Hwang","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1073\/pnas.97.9.4760","article-title":"Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses","volume":"97","author":"J\u00e4ger","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3969\/j.issn.1000-744X.2017.01.015","article-title":"Clinical study on Compound Kushen Injection combined with radioactive 125I seed implantation in the treatment of primary liver cancer","volume":"41","author":"Jiang","year":"2017","journal-title":"Guizhou Med. J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.semcancer.2005.11.006","article-title":"The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer","volume":"16","author":"Khazaie","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.13638\/j.issn.1671-4040.2020.03.023","article-title":"Clinical efficacy of Compound Kushen Injection combined with TACE in the treatment of primary liver cancer","volume":"20","author":"Li","year":"2020","journal-title":"Pract. Clin. J. Integr. Tradit. West Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3969\/j.issn.1672-0512.2021.01.008","article-title":"Effect of Compound Kushen Injection on hepatocellular carcinoma after transcatheter arterial chemoembolization combined with radiofrequency ablation","volume":"19","author":"Li","year":"2021","journal-title":"Chin. J. Integr. Tradit. West Med. Imaging"},{"key":"B25","doi-asserted-by":"publisher","first-page":"111000","DOI":"10.1016\/j.intimp.2023.111000","article-title":"Oxymatrine inhibits melanoma development by modulating the immune microenvironment and targeting the MYC\/PD-L1 pathway","volume":"124","author":"Li","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"978","DOI":"10.7501\/j.issn.1674-6376.2025.04.020","article-title":"Effect of Compound Kushen Injection combined with tislelizumab on short-term efficacy, lung function and immune function in patients with non-small cell lung cancer undergoing chemotherapy","volume":"48","author":"Li S. L.","year":"2025","journal-title":"Drug Eval. Res."},{"key":"B27","first-page":"1221","article-title":"Effect of Compound Kushen injection combined with camrelizumab and chemotherapy on efficacy and immune function in patients with advanced esophageal cancer","volume":"36","author":"Li","year":"2025","journal-title":"J. Aerosp. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3969\/j.issn.1006-2238.2024.12.014","article-title":"Efficacy of Compound Kushen injection combined with PD-1 inhibitor in the treatment of locally advanced and advanced non-small cell lung cancer and its influence on serum CEA","volume":"59","author":"Liao","year":"2024","journal-title":"Jiangxi Med. J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"747300","DOI":"10.3389\/fonc.2021.747300","article-title":"High throughput transcriptome data analysis and computational verification reveal immunotherapy biomarkers of Compound Kushen injection for treating triple-negative breast cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"965342","DOI":"10.3389\/fimmu.2022.965342","article-title":"Single-cell RNA-sequencing uncovers compound kushen injection synergistically improves the efficacy of chemotherapy by modulating the tumor environment of breast cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1077468","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.16458\/j.cnki.1007-0893.2024.08.016","article-title":"Clinical efficacy of Compound Kushen injection combined with FOLFOX4 chemotherapy regimen in the treatment of advanced liver cancer","volume":"34","author":"Liu","year":"2024","journal-title":"Shenzhen J. Integr. Tradit. West Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1455716","DOI":"10.3389\/fimmu.2024.1455716","article-title":"Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.3969\/j.issn.1008-8849.2011.36.036","article-title":"Clinical observation on Compound Kushen injection as adjuvant therapy in transcatheter arterial chemoembolization for primary liver cancer","volume":"20","author":"Lu","year":"2011","journal-title":"Mod. J. Integr. Tradit. West Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12874-022-01750-2","article-title":"How can clinicians choose between conflicting and discordant systematic reviews? A replication study of the Jadad algorithm","volume":"22","author":"Lunny","year":"2022","journal-title":"BMC Med. Res. Methodol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3969\/j.issn.2096-3327.2023.10.010","article-title":"Effect of Compound Kushen injection on chemotherapy efficacy and T-cell immunity in patients with hepatitis B-related hepatocellular carcinoma","volume":"20","author":"Lv","year":"2023","journal-title":"Chin. J. Ration. Drug Use"},{"key":"B38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.smim.2017.08.002","article-title":"Natural killer cell-mediated immunosurveillance of human cancer","volume":"31","author":"Malmberg","year":"2017","journal-title":"Semin. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1483834","DOI":"10.3389\/fimmu.2024.1483834","article-title":"The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions","volume":"15","author":"Ning","year":"2024","journal-title":"Front. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/s2468-1253(20)30014-5","article-title":"British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis","volume":"5","author":"Powell","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.13192\/j.issn.1000-1719.2024.04.034","article-title":"Observation on clinical efficacy, immune function and adverse reactions of Compound Kushen injection as adjuvant therapy in transcatheter arterial chemoembolization for primary liver cancer","volume":"51","author":"Ren","year":"2024","journal-title":"Liaoning J. Tradit. Chin. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.Can-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40164-025-00636-5","article-title":"Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential","volume":"14","author":"Tong","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3969\/j.issn.1002-266X.2009.08.058","article-title":"Efficacy observation of Compound Kushen injection via hepatic arterial perfusion in the treatment of liver cancer","volume":"49","author":"Wang","year":"2009","journal-title":"Shandong Med. J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"154315","DOI":"10.1016\/j.phymed.2022.154315","article-title":"Clinical efficacy and safety of NSCLC ancillary treatment with compound Kushen injection through immunocompetence regulation: a systematic review and meta-analysis","volume":"104","author":"Wang","year":"2022","journal-title":"Phytomedicine"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1446030","DOI":"10.3389\/fphar.2024.1446030","article-title":"Chitosan-based biomaterial delivery strategies for hepatocellular carcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B50","first-page":"24","article-title":"Mechanism study of Compound Kushen injection in alleviating chemotherapeutic adverse reactions of 5-Fluorouracil in rats with hepatocellular carcinoma","volume":"53","author":"Wang","year":"2025","journal-title":"Tianjin Med. J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"153781","DOI":"10.1016\/j.phymed.2021.153781","article-title":"Compound Kushen injection intervenes metabolic reprogramming and epithelial-mesenchymal transition of HCC via regulating \u03b2-catenin\/c-Myc signaling","volume":"93","author":"Wang","year":"2021","journal-title":"Phytomedicine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.18632\/aging.203939","article-title":"Downregulation of ZC3H13 by miR-362-3p\/miR-425-5p is associated with a poor prognosis and adverse outcomes in hepatocellular carcinoma","volume":"14","author":"Wu","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3969\/j.issn.1008-8849.2012.12.034","article-title":"Effect of Compound Kushen injection on T-lymphocyte subsets in patients with primary liver cancer treated with TACE","volume":"21","author":"Xu","year":"2012","journal-title":"Mod. J. Integr. Tradit. West Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000317","article-title":"Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib","volume":"8","author":"Yang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1002\/ctm2.410","article-title":"Rebalancing TGF-\u03b2\/Smad7 signaling via Compound kushen injection in hepatic stellate cells protects against liver fibrosis and hepatocarcinogenesis","volume":"11","author":"Yang","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3969\/j.issn.1008-0805.2022.03.75","article-title":"Meta-analysis of clinical efficacy and safety of Compound Kushen injection combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer","volume":"33","author":"Yang","year":"2022","journal-title":"Lishizhen Med. Mater Med. Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3969\/j.issn.1000-8179.20131281","article-title":"Study on the content and suppressive function of CD4+ CD25+ regulatory T cells in ascites and peripheral blood of patients with ovarian cancer","volume":"41","author":"Yao","year":"2014","journal-title":"Chin. J. Clin. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3969\/j.issn.1008-987x.2021.01.05","article-title":"Clinical efficacy of Compound Kushen injection combined with transcatheter arterial chemoembolization in the treatment of advanced liver cancer and its influence on immune regulation","volume":"23","author":"Yao","year":"2021","journal-title":"J. Hubei Univ. Chin. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.3969\/j.issn.1000-7369.2018.12.019","article-title":"Efficacy of Compound Kushen injection combined with interventional therapy in the treatment of primary liver cancer and its influence on liver function of patients","volume":"39","author":"You","year":"2018","journal-title":"Shaanxi J. Tradit. Chin. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.13501\/j.cnki.42-1590\/r.2018.04.024","article-title":"Evaluation of the effect of Compound Kushen injection as adjuvant therapy in transcatheter arterial chemoembolization for primary liver cancer","volume":"35","author":"Yuan","year":"2018","journal-title":"J. Hubei Minzu Univ. Med. Ed."},{"key":"B64","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3969\/j.issn.2095-1752.2024.33.013","article-title":"Research progress on the mechanism of Compound Kushen injection against liver cancer cells","volume":"14","author":"Yue","year":"2024","journal-title":"J. Front. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.16367\/j.issn.1003-5028.2014.10.127","article-title":"Adjuvant chemotherapy with Compound Kushen injection in the treatment of 48 cases of primary liver cancer","volume":"34","author":"Zhang","year":"2014","journal-title":"Henan J. Tradit. Chin. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.3969\/j.issn.1008-8849.2017.21.024","article-title":"Study on the effect of Compound Kushen injection combined with intraoperative margin management on postoperative recurrence and metastasis of primary liver cancer","volume":"26","author":"Zhang","year":"2017","journal-title":"Mod. J. Integr. Tradit. West Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3969\/j.issn.1673-7202.2018.03.013","article-title":"Clinical effect of Compound Kushen injection in preventing recurrence and metastasis of primary liver cancer","volume":"13","author":"Zhang","year":"2018","journal-title":"World J. Tradit. Chin. Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3969\/j.issn.2095-8552.2018.01.032","article-title":"Study on the effect of Compound Kushen injection on quality of life and therapeutic efficacy in ovarian cancer patients undergoing chemotherapy","volume":"46","author":"Zhao","year":"2018","journal-title":"Chin. J. Clin."},{"key":"B70","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","article-title":"Hepatocellular carcinoma: signaling pathways and therapeutic advances","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3969\/j.issn.1672-0369.2021.10.030","article-title":"Effect of Compound Kushen injection combined with transcatheter arterial chemoembolization in the treatment of patients with primary liver cancer","volume":"33","author":"Zhou","year":"2021","journal-title":"Chin. J. People's Health"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1715798\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:23:22Z","timestamp":1771478602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1715798\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":69,"alternative-id":["10.3389\/fphar.2026.1715798"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1715798","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"article-number":"1715798"}}